Fierce Biotech Homepage

AbbVie booth at AACR 2026
Favicon Fierce Biotech

AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’

AbbVie scrapped a phase 2 solid tumor drug after deciding that the antibody was unlikely to best current standard of care, Fierce has learned.
James Waldron Nov 3, 2026 8:38am
Pfizer
Favicon Fierce Biotech

Pfizer trims obesity pipeline, axes phase 2 lung disease asset

Nov 3, 2026 8:02am
Close-up of shredded document
Favicon Fierce Biotech

Novartis scraps $800M BioArctic brain collab after barely a year

Nov 3, 2026 4:53am
bid

Karyopharm files Chapter 11 ahead of Ayrmid merger

Nov 2, 2026 10:46am
Merck Co

For Merck, 2027 is ‘another year of investment’

Oct 29, 2026 11:23am
direction arrow

Novartis refreshes myelofibrosis bid as Geron flops in ph. 3

Oct 29, 2026 8:15am
More News
Fierce Biotech

After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs

Oct 28, 2026 9:00am
Fierce Biotech

GSK plans ‘some limited impact’ to UK roles from restructuring

Oct 28, 2026 6:33am
Fierce Biotech

Treasury COINS rules add biotech, spares China licensing deals

Oct 22, 2026 11:36pm
Fierce Biotech

AstraZeneca taps Oracle to improve recruitment for trials

Oct 20, 2026 2:36am